share_log

UBS Maintains Buy on Treace Medical Concepts, Lowers Price Target to $16

UBS Maintains Buy on Treace Medical Concepts, Lowers Price Target to $16

瑞銀維持對Treace Medical Concepts的買入,將目標股價下調至16美元
Benzinga ·  05/08 09:56

UBS analyst Danielle Antalffy maintains Treace Medical Concepts (NASDAQ:TMCI) with a Buy and lowers the price target from $17 to $16.

瑞銀分析師丹妮爾·安塔爾菲維持Treace Medical Concepts(納斯達克股票代碼:TMCI)的買入並將目標股價從17美元下調至16美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論